Evonik

Europe's transition to a circular plastics economy is losing momentum... Not exactly the headline I would hope to share when talking about the future of circular plastics. Unfortunately, that's the reality reflected in Plastics Europe’s biennial report. In the latest edition of S&P Global Recycled Polymers, I had the opportunity to put these findings into context. What stands out is the sharp slowdown in Europe's circular plastics production. Annual growth dropped from 13.6% in 2022 to just 1.2% in 2024. At the same time, global growth accelerated from 5.0% to 7.7%. From my perspective, several factors are contributing to this trend: 1️⃣ Growing volatility in the plastics market, driven by geopolitical disruptions and uncertainty across the value chain. 2️⃣ The lack of a fully connected ecosystem. Recycling involves materials that traditional waste collectors may not have handled before. Closer collaboration is essential to scale circular solutions. 3️⃣ Europe's ongoing competitiveness challenge. Companies are willing to invest, innovate, and take risks. However, competitive energy and carbon pricing remain critical prerequisites for turning those ambitions into action. The goal now is to focus on the levers we can influence. Europe needs a policy framework that strengthens industrial competitiveness while creating stronger market demand for recycled plastics. #Evonik #Competitiveness #Plastics #Circularity

🌎 From smarter crop protection and nanobubbles for food safety to advances in mRNA therapeutics: the latest edition of our ELEMENTS newsletter explores how innovation and research across North America are helping shape a more sustainable and healthier future. #Evonik #ELEMENTS #Innovation #Research

🌎 Von smarterem Pflanzenschutz über Nanobubbles für die Lebensmittelsicherheit bis hin zu Fortschritten bei mRNA-Therapeutika: Die neue Ausgabe unseres ELEMENTS-Newsletters gibt spannende Einblicke in Forschung und Innovation aus Nordamerika. #Evonik #ELEMENTS #Innovation #Research

Every molecule that leaves the desired product window reduces EBITDA. That one sentence sums up a problem most refiners quietly live with every single day. Feedstock goes in. Energy goes in. Catalyst goes in. And somewhere along the way, valuable molecules slip outside the product window you actually get paid for. Not because of bad operations. Because of chemistry limits nobody questions anymore. I will be speaking about exactly this at ERTC 2026 in Madrid. The topic is simple to say and hard to solve. How do we keep more molecules inside the value window, instead of losing them to off spec yield, unwanted byproducts, or process inefficiency. For me, this comes down to one core idea. Yield is not just an operational metric. It is a direct lever on margin, on emissions, and on how competitive a refinery stays in the next decade. Better catalysts. Smarter dewaxing. Sharper molecular management. These are not technical details. They are EBITDA decisions. If you are heading to ERTC 2026, let’s talk about how refiners can stop losing value one molecule at a time. What is your experience? Where do you see the biggest yield leakage in your own operations? #FollowUsBeyond #ERTC2026 #RefiningEfficiency #oilandgas

Celebrating another milestone for biotechnology!🚀 We just marked the start of the expansion of our biotechnology capabilities at our site in Slovakia. This is the next major step in the approximately EUR 80 million investment to strengthen our contract manufacturing services for our drug substance business. This expansion builds on decades of fermentation expertise and reinforces our commitment to innovation, operational excellence, and scalable biotechnology solutions. It also supports our Evonik asset balance strategy: building more capabilities close to our customers and close to regional demand. Biotechnology is increasingly important in pharmaceutical manufacturing. Compared with conventional chemical synthesis, fermentation-based processes can be more sustainable and competitive by reducing the need for organic solvents and minimizing process-related waste. Many thanks to everyone who has contributed to this project. I'm looking forward to following the progress of this project closely in the months ahead.💜 #Evonik #Biotechnology #Innovation #FollowUsBeyond Evonik Health Care

LNPs hold the key to the future success of RNA technology! 💉 That is why Evonik is investing over 150 million CAD in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase manufacturing capacity, helping pharmaceutical and biotech customers bring lipid-based products including vaccines and therapeutics from development through commercial scale. Lipids are essential for encapsulating and delivering nucleic acid-based drugs, including mRNA, as well as other payloads and have become a leading delivery system, underscored by their role in COVID-19 vaccines. Explore the science behind the technology and learn more about our lipid nanoparticle ecosystem in ELEMENTS, our innovation magazine. 📰 #Evonik #Invest Evonik Health Care